
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is an innovative preclinical biotechnology company with a strong focus on utilizing AI technology to develop precision antibodies, reducing risks in downstream development. Their mission is to decrease drug development timelines and bring new treatments for hard-to-target diseases. Additionally, their valuation model and lead obesity candidates, IBIO-600 and IBIO-610, show potential for investors. However, investors should be aware of potential risks such as competition and potential patent infringement suits.
Bears say
iBio is heavily dependent on partnerships and collaborations, which may impact their bottom line and could lead to delays or setbacks in their drug development. Additionally, the company has a history of reporting significant losses and negative cash flow, which could be a cause for concern for investors. This, combined with a lack of revenue and high levels of debt, make iBio a risky investment. These factors, along with potential setbacks in drug development and competition in the market, contribute to our negative outlook on the company's stock.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares